| Serial Number | 79331138 |
| Word Mark | CEBEXAN |
| Filing Date | Thursday, September 23, 2021 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, January 12, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in the field of anaesthesia; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances with analgesic properties; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical anti-allergic preparations and substances; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin diseases; pharmaceutical preparations for treating wounds; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of worms in pets; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for use in dermatology; pharmaceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for activating cellular functions; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for skin moisturizing during pregnancy; pharmaceutical preparations for adapting immunity; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations to prevent stretch marks; pharmaceutical preparations for preventing skin blemishes during pregnancy; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treating Parkinson's disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating sports related injuries; pharmaceutical preparations for treating cardiac arrhythmias; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for human use; pharmaceutical preparations for treating eye diseases and conditions; pharmaceutical preparations for treating multiple sclerosis; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the prevention of bacteria-based diseases; pharmaceutical preparations to prevent allergies; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention immune system related disorders; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of musculoskeletal diseases; pharmaceutical preparations for the prevention of diseases of the nervous system pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of endocrine system related disorders; pharmaceutical preparations for the prevention of immune system related diseases; pharmaceutical preparations for the treatment of metabolic system related diseases; pharmaceutical preparations for the prevention of the metabolic system related disorders; pharmaceutical preparations for the treatment of metabolic system related disorders; pharmaceutical preparations for the prevention of endocrine system related disorders; pharmaceutical preparations for the treatment of genitourinary system related disorders; pharmaceutical preparations for the prevention genitourinary system related disorders; pharmaceutical preparations for the prevention of metabolic system related diseases; pharmaceutical preparations for the treatment of endocrine system related diseases; pharmaceutical preparations for the prevention of respiratory system related disorders; pharmaceutical preparations for the prevention of musculoskeletal system related diseases; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for skin wounds; hair care pharmaceutical preparations; pharmaceutical preparations for treating esophagitis; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the treatment of genitourinary system related diseases; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for the treatment of bacteria-based disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of bacteria-based disorders; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for use in haematology; pharmaceutical preparations for the prevention of respiratory diseases; pharmaceutical preparations for the prevention of endocrine system related diseases; pharmaceutical preparations for the prevention of eye diseases; pharmaceutical preparations for the prevention of genitourinary system related diseases; pharmaceutical preparations for ear diseases; pharmaceutical preparations for treating epilepsy; pharmaceutical preparations for treating hypoglycaemia; pharmaceutical preparations for inhalers; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating metabolism disorders; pharmaceutical preparations for treating halitosis; pharmaceutical preparations for the treatment of digestive system related diseases; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of sensory organs diseases; pharmaceutical preparations for the treatment of radiation sickness symptoms; pharmaceutical preparations for the treatment of skeletal diseases; pharmaceutical preparations for treating rheumatic diseases; pharmaceutical preparations for treating arthritis; pharmaceutical products for injection; pharmaceutical products for the prevention of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for the prevention of diabetes; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for smoking cessation; pharmaceutical products for inducing erection; pharmaceutical products for the treatment of erectile dysfunction; pharmaceutical products for animal skincare; pharmaceutical products against diabetes; pharmaceutical products against bacteria; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical products for treating depression; pharmaceutical products for ocular use; pharmaceutical compositions; pharmaceutical moisturizing body lotion |
| Indication of Colors claimed | The colors black, green and blue are claimed as a feature of the mark. |
| Translation of Words in Mark | The wording "CEBEXAN" has no meaning in a foreign language. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 18, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | FARMAKEM d.o.o. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | SI |
| Event Date | Event Description |
| Monday, February 5, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, January 12, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, January 12, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Monday, July 3, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Wednesday, June 14, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, June 14, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Thursday, January 12, 2023 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Thursday, January 12, 2023 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Thursday, January 12, 2023 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, July 19, 2022 | REFUSAL PROCESSED BY IB |
| Thursday, June 30, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, June 30, 2022 | REFUSAL PROCESSED BY MPU |
| Wednesday, June 29, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, June 28, 2022 | NON-FINAL ACTION WRITTEN |
| Saturday, June 25, 2022 | ASSIGNED TO EXAMINER |
| Saturday, January 22, 2022 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, January 18, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, January 13, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |